To: Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>
From: Cagen, Stuart Z SCC-HSE </O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=SC724012>
Cc:
Bcc:
Received Date: 2004-01-06 13:44:46 GMT
Subject: FW: Shanghai

Patsy:

Sending this again. Note, because of the discussion on API overhead costs, I did not send this to API.

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 **Fax:** +1 713 241 3325 **Other Tel:** +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: http://www.shell.com/chemicals

-----Original Message-----
From: Cagen, Stuart Z SCC-HSE
Sent: Thursday, December 04, 2003 4:20 PM
To: Clegg, Patsy M SCC-CHSE-PC; 'Beatty, Pat (E-mail)'; 'Bill Broddle (E-mail)'; 'Brian Doll (E-mail)'; 'Burnett, Don (E-mail)'; 'Lynn Russo (E-mail)'; Tsai, Shan SP SHLOIL-SHLOIL-HE; 'mike.d.johnston@conocophillips.com'; 'stephen.m.bowes@exxonmobil.com'; 'michael.g.bird@exxonmobil.com'
Subject: Shanghai

All:

Patrick and I spoke with Rich last week about protocol changes (change in number of individuals for the ME study and inclusion of urinary metabolite for ME and adding HIV status evaluation for controls for CC), as well as the need to track the progress of the studies versus expenditures.

Rich understood and is expected to get the protocol changes into the review system within the next 4-6 weeks. He said he was already looking into ways to change the budget tracking mentality from the 'estimating' mode to something more deliberate with respect to study goals (cases). He is having some difficulty in budget tracking but expects to figure a way soon. Timing is uncertain, but I would guess this would be within the next few months, which I would guess translates to inclusion into our 1Q04 or more likely 2Q04 financial report. PATRICK WOULD YOU AGREE WITH THE ABOVE ? ANYTHING TO ADD ?

My general feeling on the above is cautious optimism as per our budget goals, but I think we should continue to be diligent on controlling our nonstudy line items. I realize we discussed this before, particularly with respect to the significant trimming of the communications budget, and fine tuning of the ERP and SRP budgets, but we might need to do more. I am open to ideas, and perhaps wait and see for the next 6-8 months might be the most likely case, but perhaps we should drill down a bit more on administrative costs (API). They are obviously providing a critical function, but maybe some of this can be replaced with our own sweat equity. Regardless, I would like to ask API for a simpler way of tracking their costs. Is this agreeable ? We don't need to come to any final decision right now, and it would be difficult to discuss this in depth without Patsy on the line on 15 Dec, but I would like the budget and oversight committees to at least discuss this.

Thanks

Stuart

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 **Fax:** +1 713 241 3325 **Other Tel:** +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: http://www.shell.com/chemicals

To: Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>
From: Cagen, Stuart Z SCC-HSE
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=SC724012>
Cc:
Bcc:
Received Date: 2004-01-06 13:47:36 GMT
Subject: FW: Shanghai

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: http://www.shell.com/chemicals

-----Original Message-----
From: Beatty, Patrick (PatrickBeatty) [mailto:PatrickBeatty@chevrontexaco.com]
Sent: Friday, December 12, 2003 2:48 PM
To: Cagen, Stuart Z SCC-HSE
Subject: RE: Shanghai

Stuart,

I agree with your characterization of our conversation with Rich. Based on a further conversation that Don and Ihad with him in Shanghai, some of the uncertainty even after tracking the number of cases is that the specifics of clinical testing will vary, patient to patient. Although he didn't mention it, the amount of effort for exposure assessment will certainly vary on a case by case basis. The best we can hope for is to establish "average" costs for these items after we have had enough cases to establish a reliable database. I suspect that would, indeed, take a year of operation.

The opening ceremony went very well. We had a tour of the lab as well, and that is looking very good. The clinical database is impressive as well. Don and I will put together a note later to go to all committee members.

I hope all is well.

Patrick

-----Original Message-----
From: Cagen, Stuart Z SCC-HSE [mailto:stuart.cagen@shell.com]
Sent: Thursday, December 04, 2003 2:21 PM
To: Beatty, Patrick (PatrickBeatty)
Subject: FW: Shanghai

Patrick:

This did not go through to you the first time

Thanks

Stuart

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: http://www.shell.com/chemicals

-----Original Message-----
From: Cagen, Stuart Z SCC-HSE
Sent: Thursday, December 04, 2003 4:20 PM
To: Clegg, Patsy M SCC-CHSE-PC; 'Beatty, Pat (E-mail)'; 'Bill Broddle (E-mail)'; 'Brian Doll (E-mail)'; 'Burnett, Don (E-mail)'; 'Lynn Russo (E-mail)'; Tsai, Shan SP SHLOIL-SHLOIL-HE; 'mike.d.johnston@conocophillips.com'; 'stephen.m.bowes@exxonmobil.com'; 'michael.g.bird@exxonmobil.com'

Subject: Shanghai

All:

Patrick and I spoke with Rich last week about protocol changes (change in number of individuals for the ME study and inclusion of urinary metabolite for ME and adding HIV status evaluation for controls for CC), as well as the need to track the progress of the studies versus expenditures.

Rich understood and is expected to get the protocol changes into the review system within the next 4-6 weeks. He said he was already looking into ways to change the budget tracking mentality from the 'estimating' mode to something more deliberate with respect to study goals (cases). He is having some difficulty in budget tracking but expects to figure a way soon. Timing is uncertain, but I would guess this would be within the next few months, which I would guess translates to inclusion into our 1Q04 or more likely 2Q04 financial report. PATRICK WOULD YOU AGREE WITH THE ABOVE ? ANYTHING TO ADD ?

My general feeling on the above is cautious optimism as per our budget goals, but I think we should continue to be diligent on controlling our nonstudy line items. I realize we discussed this before, particularly with respect to the significant trimming of the communications budget, and fine tuning of the ERP and SRP budgets, but we might need to do more. I am open to ideas, and perhaps wait and see for the next 6-8 months might be the most likely case, but perhaps we should drill down a bit more on administrative costs (API). They are obviously providing a critical function, but maybe some of this can be replaced with our own sweat equity. Regardless, I would like to ask API for a simpler way of tracking their costs. Is this agreeable ? We don't need to come to any final decision right now, and it would be difficult to discuss this in depth without Patsy on the line on 15 Dec, but I would like the budget and oversight committees to at least discuss this.

Thanks

Stuart

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987

Email: stuart.cagen@shell.com
Internet: http://www.shell.com/chemicals